Replimune REPL 深 滬
已收盤 02-06 16:00:00 美东时间
7.75
+0.820
+11.83%
華盛通- 最 高7.80
- 今 開7.14
- 成交量 172.52万股
- 最 低 7.12
- 昨 收 6.93
- 總市值 6.40亿
- 52周最高 14.7952
- 市盈率 靜 --
- 換手率 2.09%
- 52周最低 2.68
- 委 比 -81.96%
- 總股本 8257.26万
- 歷史最高 54.79
- 量 比 1.31
- 振 幅 9.81%
- 歷史最低 2.68
- 每 手 1
- 風險率 2.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 谷歌绩后获14家大行上调目标价；Arm、高通、波士顿科学、艾可菲、Snap、优步遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Wave Life Sciences Ltd."超配"评级，目标价从34美元升至41美元；Piper Sandler：维持Replimune Group"超配"评级，目标价从13美元升至14美元
02-06 16:52
美股大行评级 | 泰瑞达、Lumentum、哈贝尔、Enphase能源、西部数据获多家机构上调目标价；PayPal 、恩智浦、墨式烧烤遭多家机构下调目标价
今日重点评级关注：韦德布什：维持Replimune Group"跑赢大市"评级，目标价从18美元升至19美元；巴克莱：维持CytomX Therapeutics"超配"评级，目标价从8美元升至10美元
02-05 11:28
Wedbush Maintains Outperform on Replimune Group, Raises Price Target to $19
Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $18 to $19.
02-04 22:35
财报速睇 | Replimune 2026财年三季报营收0.00亿美元，同比增长0.0%；归母净利润亏损0.71亿美元，同比亏损扩大6.9%
Replimune 2026财年三季报营收0.00亿美元，同比增长0.0%；归母净利润亏损0.71亿美元，同比亏损扩大6.9%
02-03 23:20
财报速睇 | Replimune 2026财年三季报营收0.00亿美元，同比增长0.0%；归母净利润亏损0.71亿美元，同比亏损扩大6.9%
Replimune 2026财年三季报营收0.00亿美元，同比增长0.0%；归母净利润亏损0.71亿美元，同比亏损扩大6.9%
02-03 22:47
Replimune Group Q3 Earnings Summary & Key Takeaways
Replimune Group (NASDAQ:REPL) announced its Q3 earnings on Tuesday, February 3,...
02-03 21:38
Replimune amends Hercules loan, strengthens funding runway
Replimune Group ( ($REPL) ) has provided an update. On January 29, 2026, Replim...
02-03 21:29
Earnings Breakdown: Replimune Group Q3
Replimune Group (NASDAQ:REPL) just disclosed its Q3 earnings on Tuesday, Februa...
02-03 21:18
Replimune Group Q3 EPS $(0.77) Beats $(0.78) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.78) by 0.77 percent. This is a 2.53 percent increase over losses of $(0.79) per share from the
02-03 21:16
Replimune's Q3 net loss widens as R&D expenses rise
Replimune's Q3 net loss widens as R&D expenses rise Overview Biotechnology firm's fiscal Q3 net loss was $70.9 mln vs $66.3 mln a year ago Company preparing for RP1 launch, pending FDA approval Loan agreement amended to extend cash runway into Q1 2027 Outlook Replimune expects FDA decision on RP1 by
02-03 21:10
